FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla | AP News
WEBJul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
WEBCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the …
WEBJul 2, 2024 · Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease. Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage …
Alzhiemer's drug Kisunla from Eli Lilly gains FDA approval - USA …
WEBJul 2, 2024 · Kisunla becomes the third amyloid-clearing Alzheimer's drug approved since 2021. Last year, the FDA approved Eisai and Biogen's drug Leqembi but required the drug to provide a...
FDA approves Eli Lilly's Alzheimer's drug Kisunla - NBC News
WEBFDA approves Eli Lilly's Alzheimer's drug Kisunla. The drug, also called donanemab, is the second treatment available in the U.S. that has been shown in trials to modestly slow a decline in...
FDA approves donanemab, now Kisunla, to treat early Alzheimer's
WEBJul 3, 2024 · The U.S. Food and Drug Administration (FDA) has approved Eli Lilly ‘s antibody therapy donanemab, now Kisunla, for certain adults with Alzheimer’s disease. Specifically, Kisunla is indicated for patients with early symptomatic Alzheimer’s — to include individuals with mild cognitive impairment …
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 · Action. The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
Treatment for Early Symptomatic Alzheimer’s Disease with Kisunla ...
WEBKisunla™ (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease. Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or “ARIA.”
Skip to content